scholarly journals Interindividual Variations in Aprepitant Plasma Pharmacokinetics in Cancer Patients Receiving Cisplatin-Based Chemotherapy for the First Time

2013 ◽  
Vol 36 (4) ◽  
pp. 676-681 ◽  
Author(s):  
Shinya Motohashi ◽  
Yasuaki Mino ◽  
Katsuhito Hori ◽  
Takafumi Naito ◽  
Seiji Hosokawa ◽  
...  
Author(s):  
Sara Hayee ◽  
Amna Rehman

Caner a dreadful disease is actually one large group of diseases which dates back to times of “Hippocrates”, The Father of Medicine, (460-370BC) who used this name for the first time to talk about non-ulcer and ulcer forming tumors. Theevidence of its presence from the very past history comes from fossilized “Egyptian Mummies” having tumors on bones. Then Galen (130-200 AD) used the term “Oncos” to explain tumors. So it's a disease involving growth of abnormal cells, their proliferation and metastasizing the other tissues and organs. Now we know that biology has a branch namedOncology to deal with the scientific study of cancer and oncogenes. It took centuries to get knowledge and use modern technologies against this malady. Now we know cancer is a group disease which has hundreds of types. 19th Century saw much advancement towards its cure. Along with surgery, radiotherapy and chemotherapy were the main methods to cure cancer patients. Day by day, scientists are looking for new methods to control and cure of this curse. Hundreds of natural medicinal compounds are being tested to use clinically for its cure in order to replace the radiotherapy andchemotherapy and lower their side effects. But humanity is still fighting against this disease as the numbers of cases throughout the world are increasing day by day. If we look on the reports p r e s e n t e d b y W H O ( W o r l d H e a l t hOrganization), Cancer is the second leading cause of deaths globally which means one person in every six deaths, dies due to cancer. In 2018, the most common types of cancers reported in men were of liver, prostate, stomach, lung andcolorectal. Whereas in females the most common forms were breast, thyroid, cervical and colorectal. Cancer has become a global disasterfamily of the patient. It imparts physical, emotional and financial crisis. Unfortunately, the condition is bitterer in under developing countries. Cancer has become a lifestyle disease these days. We are living in the world withsuperficial comfort but we are breathing with urbanizations, ozone depletion, exposure to microwave and ultraviolet radiations, hazardous chemicals etc. Moreover, It is becoming a lifestyle disease due to lack of exercise, Obesity, consumptions of drugs, tobacco and alcohols. The cases of cancers are reported more in urban areas than in rural areasmore likely due to above mentioned factors. The ratio of cancer patients is expected to raise up-to 27.5 million by 2040 globally. So the battle is never ending, Humans need to figure out the factors and cutting these from their lives in orderto live a healthy life which is a blessing indeed. which is not only crunching the cancer patient but it also has damaging effects on the whole


2019 ◽  
Vol 34 (6) ◽  
pp. 1241-1241
Author(s):  
Nika Sulakvelidze ◽  
Brian Burdick ◽  
Eric Gelfand ◽  
Virginia Kaklamani ◽  
Kay Tilton ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 3558-3558
Author(s):  
D. Santini ◽  
B. Vincenzi ◽  
F. Battistoni ◽  
S. Galluzzo ◽  
L. Rocci ◽  
...  

3558 Purpose: Recent data have demonstrated in preclinical tumor models an antiangiogenic and antitumor activity of low weekly doses of ZA. As a consequence, the purpose of this study was to confirm these data, evaluating in cancer patients the modifications in angiogenic cytokines levels following repeated weekly low doses of ZA. Experimental Design: 26 consecutive cancer patients with bone metastases treated, for the first time, with four weekly doses of 1 mg of ZA followed by standard doses (4 mg every 28 days) were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) at different time points: just before and after 1, 7, 14, 21, 28, 56 and 84 days following the first disphosphonate infusion. Results: Basal serum VEGF median levels were significantly decreased just after 7 days (-29.7%) (with only one weekly infusion) (P=0.038), This significant decrease of circulating VEGF levels persisted 14(-33.2%), 21 (-39.4%), 28(-31.8%), 56(-33.6%) and 84(-27.9%) days after the first infusion (respectively, P=0.002, P=0.001, P=0.008, P=0.002, P=0.014). Conclusions: This study confirms, for the first time in humans, that weekly low doses of zoledronic acid could have antiangiogenic properties through a significant and long lasting decrease of VEGF serum levels. No significant financial relationships to disclose.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19219-e19219
Author(s):  
Natalia Vidal ◽  
Javier Puente ◽  
Fernando Moreno ◽  
María del Rosario Alfonso ◽  
Lydia Suárez ◽  
...  

e19219 Background: In the Genitourinary (GU) Cancer Unit of Clínico San Carlos Hospital the inclusion rate in Clinical-Trials (CTs) from January-October 2018 was 39%. However, in bladder cancer patients it was only 24%. We identified improvement areas in order to increase the inclusion rate of these patients up to 30% from November 2018-March 2019. Methods: We used as an instrument the American Society of Clinical Oncology (ASCO) Quality Training Program (QTP). We collected the number of proposals and available CTs, the number of bladder cancer patients evaluated for the first time and the patients enrolled in CTs. We also identified the causes of non-enrollment and elaborated a list of possible solutions. Results: We developed a cause-effect diagram showing that the most relevant causes of non-enrollment in CTs were the eligibility criteria (60%) and the absence of available CTs (35%). We created a list of measures and identified which would have a higher impact. On November 2018 we started a protocolized Supportive-Care evaluation by our Oncology nurses to increase the number of eligible patients. We also initiated the diffusion of CTs in the Investigation Unit and in the GU-board to increase the number of available CTs and recruitment. In January 2019 we implemented a Geriatric evaluation for the elderly, also to increase the number of eligible patients. With these measures the number of accepted trials increased from 5 in January-October 2018 to 12 in November 2018-March 2019. Also, in January-October 2018, 46% of patients were not-enrolled in a CT due to ineligibility, which decreased to 25% from November 2018-March 2019. As a result, the enrollment rate increased to 43, 75% from November 2018-March 2019. We maintained the measures, and achieved an enrollment rate of 54, 83% from May-December 2019. Conclusions: The implementation of a Supportive-Care and a Geriatric evaluation, and the diffusion of CTs helped increase the percentage of eligible patients and the number of available CTs. With these improvements, we were able to increase the enrollment rate in CTs from 24 to 58, 83%.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14089-14089
Author(s):  
B. Chowbay ◽  
S. Lal ◽  
X. Shu ◽  
S. Jada ◽  
L. Ooi ◽  
...  

14089 Background: The objective of this study was to screen the promoter and relevant coding regions in the UGT1A1 and UGT1A9 genes and genotypically quantitate expression of these genes in hepatic tissues obtained from Asian cancer patients undergoing hepatectomy. Methods: Non-cancerous Asian hepatic tissues (Chinese: N=36; Malay: N=1; Indian: N=3) were obtained from the institution’s central tissue repository bank. Messenger RNA was isolated from each tissue sample and reverse transcribed to cDNA followed by real time PCR experiments. Results from these gene expression experiments were normalized against GAPDH transcripts. DNA was also extracted from the hepatocytes, screened for variations in the promoter regions (UGT1A1*60, g.3140G>A and UGT1A1*28) and exon 1 (UGT1A1*6) of the UGT1A1 and UGT1A9 (UGT1A9*22, I399C>T) genes. Results: Large interindividual variations were observed in the hepatic expression pattern of UGT1A1 and UGT1A9 mRNA with respect to the different polymorphic variants. There was no significant association between hepatic expression of UGT1A1 mRNA and UGT1A1*60, g-3140G>A and *6 genotypes (P>0.05 in each case). The median expression level of UGT1A1 mRNA was approximately 2-fold higher in liver tissues harboring UGT1A1 6/6 (reference) genotype (N=27, median = 0.478; range: 0.065 to 3.125) compared to the heterozygous 6/7 genotype (N=9, median = 0.254; range: 0.042 to 1.894; P=0.77). The median expression levels of UGT1A9 mRNA were approximately 3-fold higher in liver tissues harboring I399CC genotype (N=3, median = 2.735; range: 0.702 to 3.375) when compared with the homozygous variant TT genotype (N=8, median = 0.973; range: 0.652 to 4.155; P=0.88). Conclusions: The results showed that polymorphisms in the UGT1A genes may influence the expression pattern of the respective proteins and could contribute to the high degree of interpatient variability in the glucuronidation dependent metabolism and elimination of chemotherapeutic agents in Asian cancer patients. No significant financial relationships to disclose.


2001 ◽  
Vol 75 (10) ◽  
pp. 4941-4946 ◽  
Author(s):  
F. Buseyne ◽  
M.-L. Chaix ◽  
C. Rouzioux ◽  
S. Blanche ◽  
Y. Rivière

ABSTRACT We tested seven human immunodeficiency virus-infected children for their cytotoxic T-lymphocyte (CTL) activities towards the p24 gag QASQEVKNW epitope and its nine variant sequences. Our data confirm that most, but not all, CTL responses are broadly cross-specific. For the first time, we show the high interpatient variability in cross-recognition of mutant CTL epitopes. These interindividual variations in the CTL response to the same epitope should be taken into account in the design and the evaluation of vaccines.


2019 ◽  
Vol 34 (6) ◽  
pp. 1234-1240
Author(s):  
Nika Sulakvelidze ◽  
Brian Burdick ◽  
Virginia Kaklamani ◽  
Kay Tilton ◽  
Kelsey Baker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document